2023 World Conference on Lung Cancer (Posters)-EP12.01. A Multi-Center Observational Study of Effectiveness and Safety of First Line Afatinib in Major Uncommon EGFR mutated NSCLC

EP12.01. A Multi-Center Observational Study of Effectiveness and Safety of First Line Afatinib in Major Uncommon EGFR mutated NSCLC - PDF(Abstract)

Back to course

Pdf Summary

This study evaluated the effectiveness and safety of afatinib, a second-generation EGFR-tyrosine kinase inhibitor, in treating non-small cell lung cancer (NSCLC) with major uncommon EGFR mutations in Vietnam. The study included data from 80 patients who initiated first-line afatinib treatment between January 2018 and June 2022 at nine oncology centers in Vietnam. The primary outcome of the study was time to treatment failure (TTF), and secondary outcomes included objective response rate (ORR), disease control rate (DCR), and overall survival (OS). <br /><br />The results showed that afatinib had a median TTF of 14.7 months, an ORR of 79%, and a DCR of 92% in the overall population. Among patients with brain metastases, afatinib demonstrated an intracranial ORR of 56% and a DCR of 100%. The study also found that afatinib was effective against different uncommon EGFR mutations, including G719X, L861Q, S768I, and compound mutations. Patients with brain metastases at baseline had worse survival outcomes, and those with liver metastases had inferior TTF. However, the number of patients with liver metastases was small. Median OS was not reached, and the survival rate at 18 months was 82%. Rash was the most common adverse event associated with afatinib treatment.<br /><br />In conclusion, afatinib was found to be an effective treatment option for Vietnamese NSCLC patients with major uncommon EGFR mutations. It demonstrated a favorable survival outcome, high response rate, and manageable tolerability profile. Brain and liver metastases were identified as poor prognostic factors. The incidence of the secondary T790M mutation, which is often observed in common EGFR mutations, was lower in patients with major uncommon EGFR mutations.

Asset Subtitle

Anh Le

Meta Tag

Speaker Anh Le

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

afatinib

EGFR-tyrosine kinase inhibitor

non-small cell lung cancer

NSCLC

major uncommon EGFR mutations

Vietnam

time to treatment failure

objective response rate

disease control rate

overall survival